EntreMed Reports Results From Phase 2 Study of Panzem.

0 Comments | M2 Presswire, June, 2007

M2 PRESSWIRE-5 June 2007-ExplorationInvestor: EntreMed Reports Results From Phase 2 Study of Panzem(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:05062007 Exploration Investor strives to provide you with outstanding market results. We will be your number one resource for all your small and large cap needs.

While working to keep you in touch with market activity, we also will keep you updated on the latest press. Today we have identified, EntreMed, Inc. (NASDAQ: ENMD) due to the attention they received after this recent corporate development. EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today, June 5th, the presentation of results of a single-agent...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)